


# Genbioma

**Improving Metabolic Health  
Through  
Microbiome Science**



## About us


**Product development platform** of next generation, **clinically validated –biotics** for **cardiometabolic health** through **microbiome balance**

**Diabetes (T2 & PreD)**


**Obesity**

**Cholesterol**

**Arterial hypertension**



## From bench to market



## Genbioma Overview

We create **next-generation of postbiotics for cardiometabolic health powered by microbiome science.**

- **Experienced cross-disciplinary team**, fully integrated to accelerate growth and long-term success.
- **Platform for rapid health evidence** that reduces R&D time and cost, de-risking every step from discovery through clinical validation.
- **Comprehensive IP strategy** that locks in competitive advantage and maximizes long term value.
- Extensive **network of scientific, commercial, and industrial partners** strategically aligned.
- **Lean model**, with **top-tier CDMOs partners**, for elastic capacity, rapid scale up, **and GMP quality.**
- **First revenues forecast for 2025**, providing early market validation and momentum.
- **Robust pipeline of next-generation products.**

3.8M€

Total funding

7

Employees  
(5 PhDs)

2

patent families in 34  
Countries

1<sup>st</sup>

Clinically validated  
product


## A unique screening platform

From petri dish to market-ready postbiotics in record time

Genbioma has validated a development **platform for rapid identification** and functional profiling of new microbiome-based solutions.

### Cuts cost, risk and time to market

- Array of validated assays for glucose, lipid and cardiovascular metabolism using *C. elegans* model.
- Integrated metagenomics & metabolomics to unveil mode-of-action early.
- Regulatory filters baked in: Safety, IP and regulatory checkpoints for early candidate de-selection.
- Human Validation: Real-World Evidence & Clinical Trials



## Successful first launch!



### pA1c®HI Postbiotic ingredient

#### *First postbiotic for glucose control*

- Clinically validated to **maintain glycemic control** in Prediabetes and Type-2 Diabetes.
- Available in capsules as **dietary supplement**, or as bulk powder for **Food Industry**.
- **First Distribution agreement in 6 EU countries** (as nutraceutical Reglubetic®HI).



## pA1c®HI Postbiotic ingredient

First clinically proven postbiotic for glucose control

### Premium postbiotic ingredient with unrivalled scientific validation

- **Multi-target impact:** Re-balances gut microbiota, lowers HbA1c, increases GLP-1 levels. Enhances metabolic balance and improves key anthropometrics
- **Clinically proven efficacy:** Significant improvement in glucose and lipid related parameters, plus a marked reduction in bacteria linked to metabolic disorders
- **Exceptional tolerability:** >99 % study adherence and an excellent safety profile across all trials



- ✓ **+10** positive preclinical studies (*C. elegans* and rodents)
- ✓ **+2** Positive human studies (Clinical Trials & Real World)
- ✓ **+10** publications in international Sci. journals
- ✓ **+15** communications at conferences
- ✓ **+30 AWARDS**

Diabetologia

Food &  
Function

International Journal of  
*Molecular Sciences*





## OUR TEAM

Seasoned founders and a multidisciplinary core team powering microbiome innovation.

### FOUNDERS



Josune Ayo, PhD  
**Co-founder, investor & CEO**  
*Top 60 EU Woman AgriFood 2024*  
*EIC WLP 2023*



Goyo Sanzol  
**Co-Founder & President**  
*CEO +3 startups*  
*Postbiotics for animal health*



Prof. Miguel Barajas, PhD  
**Co-Founder & CTO**



Prof. Ignacio Encío, PhD  
**Co-Founder**



Luis Gosálbez, PhD  
**Non-Executive  
Business Development  
Director**



Eva Sáez  
**CFO**



Iñaki Iturria, PhD  
**Business Development  
Manager**



Angela Moncada, PhD  
**R&D Manager**



Deyan Yavorov, PhD  
**R&D Project Manager**



Leyre Iriarte  
**R&D Technician**

### TEAM



## BUSINESS MODEL

### Partner-Centric B2B Model

*Accelerating Market Access*



#### Nutraceutical & Pharma

*Evidence-driven companies seeking differentiated microbiome solutions*



#### Healthy Food Sector

*Ready meal, beverage & functional food players searching for metabolic health ingredients*

### How we create value

We partner with nutraceutical distributors, contract manufacturers, ingredient suppliers, and healthy-food & beverage producers to speed innovation and market entry.

- **Tailor-made actives.** Development of postbiotic ingredients tuned to each product matrix and region.
- **Prototype co-creation.** Rapid pilot of gummies, flash bags, fortified drinks and other on-trend formats.
- **Flexible deals.** Supply, co-development or licensing agreements to match any risk-return profile.
- **End-to-end support.** Regulatory, clinical-evidence and scale-up guidance that de-risks the path from lab to shelf.

### Tailored Delivery Formats



Active Ingredient  
in Bulk Powder



Ready-to-Market  
capsules



Innovative formats



## INTELLECTUAL PROPERTY STRATEGY



### 2 Patent Families

EP 407684 granted with unitary effect in 23 EU states + UK (glucose control strain CECT 9879) – divisional and US/HK filings active.

New EP 24382308.5 (2024) and parallel US filing cover postbiotic for obesity.



### 5 Trademarks

GENBIOMA®, pA1c®, Reglubetic®, Reglubetic HI® registered in EU, UK, US.

pA1c® also secured in nine Asia-Pacific markets (JP, KR, SG, MY, IN, VN, PH, AU, TH).



### 3 Biological deposits

*P. acidilactici* bacterial strains deposited:

CECT 9879, 9889, 9967



### Regulatory approvals

QPS (EFSA) and GRAS (FDA) obtained for pA1c® and pA1c HI®.

Inactivation process protected as industrial secret.

Finished products notified in ES, PT, FR, IT.



# Commercial traction to date pA1c®HI

## Commercial milestones

### 1<sup>st</sup> Sales Contract

6 countries of Balkan Region

### 4 new distribution agreement in an advance stage of negotiation

across US, EU & LATAM distributors

### 4 Industry Co-developments

with healthy food industry



## Lead pipeline

### From May 2025

+55 Qualified Leads → 25 in dialogue → 10 ongoing negotiations



## Why Invest in Genbioma?



Clinically-tested and patented of pA1c<sup>®</sup>HI postbiotic for Glucose Control



Experienced R&D teams



Biotech platform & pipeline for –biotics for cardiometabolic health




International agreements expected within 6–12 months



Solid financial structure + investors

# FUNDRAISING

**Open new investment round 2M€ (equity) to reach the break event (2027) in order to:**



The background of the slide is a light blue, semi-transparent image showing a microscopic view of various bacteria, including several large, oval-shaped cells with internal structures.

# Genbioma

**Thank you**  
**Gracias**

**Josune Ayo, PhD**  
CEO and Founder  
[josune@genbioma.com](mailto:josune@genbioma.com)

[genbioma.com](http://genbioma.com)